Researchers from Chantibody Therapeutics Inc. presented the preclinical characterization of CT-111, a trispecific antibody engineered to simultaneously target PD-1, CTLA-4, and VEGF.
Arginase 1 (Arg1) is a key mediator of immune suppression, and its overexpression has been reported in multiple cancers, including renal cell carcinoma, pancreatic cancer, and head and neck cancer. However, clinical strategies aimed at inhibiting Arg1 function have achieved only limited success.
At the 2025 annual meeting of the Society for Neuroscience in San Diego this week, Catherine Woolley’s plenary lecture was an unusual combination of debunking and affirming the importance of sex differences in the brain.
The health care sector continues to be strong and adaptable despite the challenges over the past year, according to a report by global investment bank Jefferies. High interest rates, geopolitical uncertainty and policy shifts have added caution to the industry, but leaders are adapting well.
Although tricomplex pan-RAS (ON) inhibitors, such as RMC-6236, constitute a promising class of therapeutics against RAS-driven cancers, their on-target, off-tumor toxicities challenge the dosing strategy and the safety of drug combinations.
Inactivation of the tumor suppressor p53 occurs in approximately half of human cancer cases. In particular, the Y220C point mutation, which induces p53 misfolding and inactivation, is found in about 1% of solid tumors. Previous research identified a unique, druggable pocket on the p53 surface created by this mutation that constitutes a promising cancer therapeutic target.
In glioblastoma multiforme, MTAP loss leads to MTA accumulation, which partially inhibits PRMT5, making the cells reliant on residual PRMT5 activity for survival. Targeting this remaining PRMT5 with MTA-cooperative inhibitors induces synthetic lethality, representing a promising targeted approach for MTAP-deleted gliomas. Researchers from Ryvu Therapeutics SA reported the preclinical profile of RVU-305, a PRMT5 inhibitor, in MTAP-deleted cancer models.
In preclinical studies at Sunshine Lake Pharma Co. Ltd., researchers investigated the antiviral and immune-modulatory potential of HEC-191834, a novel and highly selective human Toll-like receptor 8 (TLR8) agonist, in chronic hepatitis B virus (HBV) models, as well as its activity when combined with siRNA.
The inhibition of PD-L1 and VEGF individually or in combination has shown efficacy across several solid tumor types, but not all patients respond to therapy or respond for short duration. IMM-2510 is a novel bispecific antibody developed by Immuneonco Biopharmaceuticals Inc. that targets both PD-L1 and VEGF, thus achieving both angiogenesis inhibition and immune checkpoint blockade.
RSS
